Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 247-249

  Kako, Shinichi ^a   Kanda, Yoshinobu ^a   Oshima, Kumi ^a   Nishimoto, Nahoko ^a   Sato, Hiroyuki ^a   Watanabe, Takuro ^a   Hosoya, Noriko ^b   Motokura, Toru ^a   Miyakoshi, Shigesaburo ^c   Taniguchi, Shuichi ^c   Kamijo, Aki ^b   Takahashi, Koki ^b   Chiba, Shigeru ^b   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CIDOFOVIR; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PROBENECID; RITUXIMAB;

ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD GROUP ABO INCOMPATIBILITY; CASE REPORT; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RADIATION DOSE; REFRACTORY ANEMIA WITH EXCESS BLASTS; RETINITIS; RISK FACTOR; SYMPTOM; T CELL DEPLETION; WHOLE BODY RADIATION;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RED-CELL APLASIA, PURE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 39749095981     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21086     Document Type: Article

References (20)

1. Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988;45:530-534.
2. Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990;75:290-295.
3. Malfuson JV, Amor RB, Bonin P, et al. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation. Vox Sang 2007;92:85-89.
4. Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;17:1093-1099.
5. Chen FE, Owen I, Savage D, et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 1997;19:491-495.
6. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-3861.
7. Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant 2002;29:365-366.
8. Raj K, Narayanan S, Augustson B, et al. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;35:299-301.
9. Sora F, De Matteis S, Piccirillo N, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005;45:643-645.
10. Dungarwalla M, Marsh JC, Tooze JA, et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: Implications for their pathophysiology. Ann Hematol 2007;86:191-197.
11. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005;79:1351-1357.
12. Sosler SD, Behzad O, Garratty G, et al. Immune hemolytic anemia associated with probenecid. Am J Clin Pathol 1985;84:391-394.
13. Kickler TS, Buck S, Ness P, et al. Probenecid induced immune hemolytic anemia. J Rheumatol 1986;13:208-209.
14. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 2000;95:352-359.
15. Crowley B, Woodcock B. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab. Br J Haematol 2002;119:279-280.
16. Herbert KE, Prince HM, Westerman DA. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood 2003;101:1654.
17. Thachil J, Salim R. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia. Leuk Res 2007;31:1025-1026.
18. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867-874.
19. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;36:813-819.
20. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-4363.